Lu Q. Le

Tumor microenvironment and neurofibromatosis type I: connecting the GAPs.

Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.

Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors.

BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction.

Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibroma.

Cutaneous neurofibromas in the genomics era: current understanding and open questions.

The biology of cutaneous neurofibromas: Consensus recommendations for setting research priorities.

Spatiotemporal Loss of in Schwann Cell Lineage Leads to Different Types of Cutaneous Neurofibroma Susceptible to Modification by the Hippo Pathway.

NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.

Double-Stranded RNA Sensing Determines Epithelial Cell Identity.

Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.

Heterozygous Tumor Suppressor Microenvironment in Cancer Development.

Translating current basic research into future therapies for neurofibromatosis type 1.

Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing.

Tumorigenesis in neurofibromatosis type 1: role of the microenvironment.

Neurofibromin and suppression of tumorigenesis: beyond the GAP.

Malignant peripheral nerve sheath tumor: models, biology, and translation.